Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sézary syndrome: A European society for blood and marrow transplantation lymphoma working party extended analysis

We previously reported (J Clin Oncol 28:4492-4499, 2010) an overall survival (OS) of 66% at 1 year and 54% at 3 years after allogeneic hematopoietic cell transplantation (HCT) in patients with advanced-stage mycosis fungoides and Sezary syndrome (MF/SS). Here, we present an extended analysis of this experience, with a median follow-up in survivors of 7 years (longest follow-up: 12 years; interquartile range: 6 to 9 years). Our data show that patients with advanced-stage MF/SS continue to benefit from allogeneic HCT over time, with an OS of 46% at 5 years and 44% at 7 years (95% CI, 35% to 61% and 33% to 59%, respectively), and a PFS of 32% at 5 years and 30% at 7 years (95% CI, 22% to 47% and 20% to 45%, respectively). Our results, from the largest series on this topic published to date, now updated with a prolonged median follow-up of 7 years, provide a clearer picture of the value of allogeneic HCT as a therapeutic strategy for high-risk patients with advanced-stage MF/SS and further support the existence of a clinically relevant and persistent graft-versus-MF/SS effect.